OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Another licence agreement, more good news just the start to what should be a massive yr for oxb.

We do seem to have a persistent seller,25k 10k though the trades list doe's not reflect the true amount of buying, some of the other sells are infact buys.

rvitler, you're right. More good news but, as always, the SP does absolutely f**k all. What on earth does this one need to start it heading skywards?

And now its below where it was before the announcement on the 5th! Heaven help us if they ever get any bad news....or perhaps the SP will actually go up!

About to explode?....

or implode?....

we need some good positive trial results on this one.

positive news so it can go down you mean. COME ON!!! you b***ard thing get moving up

Love the comment AMharry4899 - I think you captured all our thoughts! Agree, so frustrating when if in the US, this co's sp would be 20 times the price.

Aaah...20x...that would pay for tonight's bottle of wine...

Someone has just acquired 3% OF THE CO and the shares still go down. If I sold some the sp would shoot up, so lets just say i've sold today.

OXB is really not getting places - it has been in this region of 16-19p for ages.

OXB shall be a success story of 2005-6, with licence agreements underpinning the development budget. I keep buying around 17p. I hold 120,000 stock. management are really excellent, with the best contacts in the business. They are almost above th3e biz .. like British Bio should have been , but got tainted . Prof Kingsman didn't let himself be so influenced.
You should see 30p tested by summer .If not later in the year, thanks to Trovax and other developments. if you are intersteed in increasing a sum of cash from X to X plus 50% in one year, this is such a company. If you want to do it ina fortnight, try the pools.

It's time to get back in - with the sellers out the way, and price hitting 17 again, good news to come will push this overlooked Gem up above 20 and the graph will show a golden cross meaning onwards and upwards this yr to 45p

3 companies have acquired a sizeable stake, who are the Sputnik Group? Let's hope they don't get taken over as I want these long term as they're going to be worth many pounds. Something's afoot anyway, Trovax is coming of age and will be a rael money spinner, the other technologies are so awesome, they're just too difficult to understand but the applications are endless and worth a fortune, no reason for this low price.

Another licence deal would kick start it or news of the trials, there's a lot of newsflow tocome, progress reports and possible big deals so price could take off.

Some very good buys - 500k etc so why the sudden interest?

rvitler- not sure but is it a coincidence that Cenes (CEN), who I also hold shares in, has the same upward movement???

Used to have that one yrs ago, but not quite in OXB league, I strogly believe that 05 will be OXB breakout yr and 50p +

Some suggestion from sources unknown (London broker) that OXB might be a possible target. Nothing known - and could easily be a rumour started to drum up some trading in OXB.

Oxford Biomedica PLC
19 January 2005




NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN


Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')

Response to share price movement

The Board of Oxford BioMedica notes the recent movement in the Company's share
price. The Board confirms that it has received an approach from a third party
and that it is in discussions regarding a potential merger.

The Board wishes to stress that discussions are at an early stage and may or may
not lead to an offer for the Company.

19 January 2005


Enquiries:
Oxford BioMedica plc Tel: +44 (0) 1865 783000
Professor Alan Kingsman, Chief Executive Officer
Andrew Wood, Chief Financial Officer






This information is provided by RNS
The company news service from the London Stock Exchange